Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Francisca Giselle Rocha Moura"'
Autor:
Tiago Felismino, Celso Abdon Lopes de Mello, Samuel Aguiar Junior, Francisca Giselle Rocha Moura, Rachel P. Riechelmann, Victor Hugo Fonseca de Jesus, Bruno Cezar de Mendonça Uchóa Junior
Publikováno v:
ecancermedicalscience
Background CAPOX regimen is a standard option in stage III adjuvant colon cancer. Gastrointestinal toxicity is well described with fluoropyrimidine regimens and can be life-threatening. Identification of risk factors associated with severe gastrointe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::778a178586df8c5434b5957affb259b1
https://pubmed.ncbi.nlm.nih.gov/32256697
https://pubmed.ncbi.nlm.nih.gov/32256697
Autor:
Éverton Melo, Tiago Felismino, Luciana Beatriz Mendes Gomes Siqueira, Juliana Rosa Chinelato, Bruno Cezar de Mendonça Uchôa, Jose Ecio Batista Rosado, Victor Hugo Fonseca de Jesus, Ana Paula Rondina Correa, Francisca Giselle Rocha Moura, Marcelle Goldner Cesca, Rafaela Pirolli, Mauro Daniel Spina Donadio
Publikováno v:
Journal of Clinical Oncology. 39:e16086-e16086
e16086 Background: The role of HER2 positive (HER2+) as a prognostic biomarker for gastric/gastroesophageal junction cancer (G-GEJC) is controversial. Recently, the HER2-low (HER2l) concept has emerged and proved to predict response to trastuzumab de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9f4a69cf1f97491c9ac509b18a662e49
https://doi.org/10.1200/jco.2021.39.15_suppl.e16086
https://doi.org/10.1200/jco.2021.39.15_suppl.e16086